Collegium Q2 net revenue $135.5M (+10% YoY); GAAP net income $13.0M vs loss; authorizes $50M buyback

COLLEGIUM PHARMACEUTICAL, INC

2023-Q2 EPS reported -$0.13 revenue$280,313,000

Q2 GAAP net income $13.0M ($0.34 diluted EPS) vs GAAP net loss of $5.2M a year ago; adjusted EBITDA $85.8M, up 21% YoY.
Board authorized $50M accelerated share repurchase program; reaffirmed FY2023 guidance product revenue $565-580M, adjusted EBITDA $355-370M.
Xtampza ER revenue grew 24% YoY to $41.2M; Nucynta franchise revenue up 8% YoY to $47.3M; Belbuca prescriptions up 3.5% QoQ.
FDA approved Nucynta for children ages 6+; pediatric extension could extend exclusivity to Dec 2025.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

COLLEGIUM PHARMACEUTICAL, INC reported quarter ended June 30, 2023 results: revenue $135.5 million, net income $13.0 million, EPS $0.34 GAAP earnings per share (diluted). Guidance reaffirmed.

Period: quarter ended June 30, 2023
Revenue: $135.5 million
Net income: $13.0 million
EPS: $0.34 GAAP earnings per share (diluted)
Guidance: reaffirmed
Result: reported results

Exact text from the filing

of this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- Collegium Reports Record 1H’23 Net Revenue of $280.3 Million, Up 35% Year-over-Year – Q2’23 Net Revenue of $135.5 Million, Up 10% Year-over-Year – – Q2’23 GAAP Net Income of $13.0 Million – – Q2’23 Adjusted EBITDA of $85.8 Million, Up 21% Year-over-Year – – Board of Directors has Authorized

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

COLLEGIUM PHARMACEUTICAL, INC filing history →

Source: SEC EDGAR

accession 0001558370-23-013191

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.